Skip to main content
Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
2.750
-0.030 (-1.08%)
Dec 20, 2024, 4:00 PM EST - Market closed

Puma Biotechnology Revenue

Puma Biotechnology had revenue of $80.54M in the quarter ending September 30, 2024, with 43.53% growth. This brings the company's revenue in the last twelve months to $243.57M, up 6.30% year-over-year. In the year 2023, Puma Biotechnology had annual revenue of $235.64M with 3.34% growth.

Revenue (ttm)
$243.57M
Revenue Growth
+6.30%
P/S Ratio
0.55
Revenue / Employee
$1,316,589
Employees
185
Market Cap
134.99M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023235.64M7.61M3.34%
Dec 31, 2022228.03M-25.12M-9.92%
Dec 31, 2021253.16M28.05M12.46%
Dec 31, 2020225.11M-47.15M-17.32%
Dec 31, 2019272.26M21.27M8.47%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Nevro 419.15M
Pro-Dex 56.80M
Metagenomi 55.08M
Vaxart 16.76M
Seer, Inc. 14.61M
Aligos Therapeutics 6.00M
Revenue Rankings

PBYI News

More News